Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Director Sells $30,088,098.88 in Stock

Moderna, Inc. (NASDAQ:MRNAGet Free Report) Director Noubar Afeyan sold 202,832 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the sale, the director now directly owns 1,528,557 shares of the company’s stock, valued at approximately $226,746,145.38. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Noubar Afeyan also recently made the following trade(s):

  • On Wednesday, June 5th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $151.25, for a total transaction of $2,268,750.00.
  • On Wednesday, May 29th, Noubar Afeyan sold 20,000 shares of Moderna stock. The shares were sold at an average price of $145.08, for a total transaction of $2,901,600.00.
  • On Wednesday, May 22nd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $157.57, for a total transaction of $2,363,550.00.
  • On Wednesday, May 15th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $127.32, for a total transaction of $1,909,800.00.
  • On Wednesday, May 8th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $121.68, for a total transaction of $1,825,200.00.
  • On Wednesday, May 1st, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00.
  • On Wednesday, April 24th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $108.32, for a total transaction of $1,624,800.00.
  • On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $103.38, for a total transaction of $1,550,700.00.
  • On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $107.12, for a total transaction of $1,606,800.00.
  • On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total transaction of $1,525,200.00.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $145.23 on Friday. The company has a market capitalization of $55.66 billion, a price-to-earnings ratio of -9.27 and a beta of 1.54. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $170.47. The firm’s 50-day moving average is $128.21 and its 200 day moving average is $107.72. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNAGet Free Report) last issued its earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. The business had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.19 EPS. Research analysts predict that Moderna, Inc. will post -7.46 EPS for the current year.

Hedge Funds Weigh In On Moderna

Hedge funds have recently added to or reduced their stakes in the stock. Ogorek Anthony Joseph NY ADV bought a new position in Moderna in the 4th quarter worth about $27,000. Arlington Trust Co LLC grew its stake in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after acquiring an additional 290 shares in the last quarter. Cedar Wealth Management LLC grew its stake in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares in the last quarter. Westside Investment Management Inc. bought a new position in Moderna in the 1st quarter worth about $32,000. Finally, Rise Advisors LLC lifted its position in shares of Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after purchasing an additional 286 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MRNA has been the topic of several research analyst reports. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Jefferies Financial Group restated a “buy” rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Monday, June 3rd. Oppenheimer boosted their target price on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Canaccord Genuity Group boosted their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $129.02.

Check Out Our Latest Stock Analysis on Moderna

Moderna Company Profile

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

See Also

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.